Tarnow, L.

igf-i patient diabetes study treatment baseline level renin type 1 diabetes type 2 diabetes subject effect reduction lisinopril renin inhibition igf-i gene polymorphism signi ficantly variant type igf-i levels aliskiren blood signi polymorphism growth washout albuminuria variant plasma allele nephropathy change lisinopril 40 mg value table inhibition serum insulin journal ficantly factor albumin igf-i gene pressure lisinopril 20 mg endocrinology period blood pressure follow-up inhibitor post-treatment washout insulin-like prorenin 28 days raas blockade kidney hypertension treatment period plasma renin activity angiotensin protein method difference microalbuminuria ang i promoter 24 h sbp sample albumin excretion rate result 24 h abp onset concentration genotype receptor 0–5 activity 60 mg diabetes mellitus post-treatment rossing